GlassScriptPhysician profile
Ryan D Kunstadt
NPI 1861836694
$1,739.68
in general payments reported to CMS, 2019-2025
21 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.42 · 2021: $260 · 2022: $239 · 2023: $346 · 2024: $493 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.38 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $418.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $312.28 | 2019-2025 | Evenity, Tepezza, Prolia |
| Corcept Therapeutics | $207.04 | 2023-2025 | Korlym |
| Horizon Therapeutics Plc | $117.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $78.36 | 2023 | |
| Insulet Corporation | $72.18 | 2019-2025 | Omnipod |
| Mannkind Corporation | $68.73 | 2024-2025 | |
| Medtronic, INC. | $67.01 | 2021-2025 | Minimed 780g |
| Astellas Pharma US INC | $53.98 | 2023-2024 | Veozah |
| Verity Pharmaceuticals INC. | $52.71 | 2024-2025 | Tlando |
| Abbott Laboratories | $43.00 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $41.86 | 2023-2024 | |
| Beta Bionics, INC. | $38.23 | 2024 | Ilet Bionic Pancreas |
| Lilly USA, LLC | $33.10 | 2022 | |
| Dexcom, INC. | $30.48 | 2023 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $24.04 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.66 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $17.37 | 2023 | |
| Abbvie INC. | $15.99 | 2024 | |
| Tolmar, INC. | $13.23 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kunstadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.